Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlueCross Tennessee Ipilimumab Prior Auth | OpenPa…
    Ask Trek AI about this page
    DraftBlueCross BlueShield of TennesseePolicy ID_CHS_17962026a_1026

    Ipilimumab (Yervoy) Coverage Criteria

    Customize your policy alerts

    Sign up for blue cross blue shield - tennessee Policy ID_CHS_17962026a_1026 alerts

    Get alerted when Policy ID_CHS_17962026a_1026 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for ipilimumab (Yervoy), alone or in specified combinations, for FDA-approved and compendial oncology indications. Covered use requires satisfaction of the applicable approval criteria and absence of exclusions; all other indications are considered experimental/investigational and not medically necessary.

    Policy Summary
    PayerBlueCross BlueShield of Tennessee
    PolicyIpilimumab (Yervoy) Coverage Criteria
    Policy CodePolicy ID_CHS_17962026a_1026
    Change TypeNo material clinical or coverage changes
    Effective DateDec 31, 202642d
    Next Review DateN/A
    Key ActionSubmit laboratory documentation confirming MSI-H, dMMR, or POLE/POLD1 tumor status when applicable.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    8FDA-approved indication categories
    6 monthsStandard authorization period
    18Cancer indication groups
    NivolumabCommon combination partner

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥10 mut/Mb
    Bone cancer TMB threshold
    IntravenousRoute of administration

    Covered Indications and Eligibility

    General Covered Indications

    The following FDA-approved indications and compendial uses are covered when all applicable approval criteria are met and the member has no exclusions to the prescribed therapy.

    ALL of the following

    • FDA-approved indications

      • Unresectable or metastatic melanoma in adult and pediatric patients 12 years and older, as a single agent or in combination with nivolumab.
      • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.
      • First-line treatment of adult patients with intermediate- or poor-risk advanced renal cell carcinoma, in combination with nivolumab.
      • Treatment of adult and pediatric patients 12 years and older with unresectable or metastatic MSI-H or dMMR colorectal cancer, in combination with nivolumab.
      • First-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma, or treatment after prior sorafenib, in combination with nivolumab.
      • First-line treatment of adult patients with metastatic NSCLC whose tumors express PD-L1 at 1% or greater, with no EGFR or ALK genomic tumor aberrations, in combination with nivolumab.
      • First-line treatment of adult patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy.
      • First-line treatment of adult patients with unresectable malignant pleural mesothelioma, in combination with nivolumab.
      • First-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 at 1% or greater, in combination with nivolumab.
    • Compendial uses

      • Adrenal gland tumors; ampullary adenocarcinoma; appendiceal neoplasms and cancers; biliary tract cancers, including cholangiocarcinoma and gallbladder cancer; bone cancer; central nervous system brain metastases; cervical cancer; colorectal cancer, including anal adenocarcinoma; cutaneous melanoma; esophageal or esophagogastric junction cancers; gastric cancer; gestational trophoblastic neoplasia; hepatocellular carcinoma; Kaposi sarcoma; Merkel cell carcinoma; non-small cell lung cancer; ovarian, fallopian tube, or primary peritoneal cancer; peritoneal or pleural mesothelioma; renal cell carcinoma; small bowel adenocarcinoma; soft tissue sarcoma, including angiosarcoma, borderline or malignant phyllodes tumor, dedifferentiated liposarcoma, epithelioid hemangioendothelioma, extremity or body wall sarcoma, head or neck sarcoma, pleomorphic rhabdomyosarcoma, and retroperitoneal or intra-abdominal sarcoma; uterine neoplasms, including endometrial carcinoma and uterine sarcoma; uveal melanoma; vaginal cancer; and vulvar cancer.

    Adrenal Gland Tumors

    Covered when the following criterion is met:

    ALL of the following

    • Treatment is in combination with nivolumab for unresectable or metastatic adrenocortical carcinoma.Authorization: 6 months

    Ampullary Adenocarcinoma

    Covered when the following criterion is met:

    ALL of the following

    • Treatment is in combination with nivolumab for 4 doses followed by nivolumab as a single agent for progressive or metastatic MSI-H or dMMR ampullary adenocarcinoma.Authorization: 6 months

    Adrenal Gland Tumors — Combination and Disease Status

    Covered when the following criterion is met:

    ALL of the following

    • Treatment is in combination with nivolumab for unresectable or metastatic adrenocortical carcinoma.Authorization: 6 months

    Ampullary Adenocarcinoma — Disease, Biomarker, and Regimen

    Covered when ALL of the following are met:

    ALL of the following

    • Disease is progressive or metastatic ampullary adenocarcinoma.
    • The tumor is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
    • Treatment is in combination with nivolumab for 4 doses followed by nivolumab as a single agent.

    Appendiceal Neoplasms and Cancers

    Covered when ALL of the following are met:

    ALL of the following

    • Disease is an appendiceal neoplasm or appendiceal cancer, including appendiceal adenocarcinoma, goblet cell adenocarcinoma, or undifferentiated carcinoma not otherwise specified.
    • The tumor is MSI-H, dMMR, or has a POLE/POLD1 mutation with an ultra-hypermutated phenotype, such as TMB greater than 50 mut/Mb.
    • Treatment is in combination with nivolumab for 4 doses followed by nivolumab as a single agent.

    Biliary Tract Cancer

    Covered when either treatment setting and its associated requirements are met:

    ANY of the following

    • Subsequent treatment

      • Disease is unresectable or gross residual (R2), or metastatic extrahepatic or intrahepatic cholangiocarcinoma or gallbladder cancer.
      • The tumor is tumor mutational burden-high (TMB-H).
      • Treatment is in combination with nivolumab.
    • Neoadjuvant treatment

      • Disease is resectable, locoregionally advanced gallbladder cancer.

    Bone Cancer

    Covered when ALL of the following are met:

    ALL of the following

    • Disease is unresectable or metastatic bone cancer.
    • Tumor is TMB-H, defined as at least 10 mut/Mb.
    • Disease has progressed following prior treatment and there are no satisfactory alternative treatment options.
    • Treatment is in combination with nivolumab.

    Central Nervous System Brain Metastases

    Covered when the following criteria are met:

    ALL of the following

    • Member has CNS brain metastases from BRAF-nonspecific melanoma.
    • Treatment is a single agent or in combination with nivolumab for 4 doses followed by nivolumab as a single agent.

    Cervical Cancer

    Covered when ALL of the following are met:

    ALL of the following

    • Treatment is in combination with nivolumab.
    • ANY of the following

      • Disease is recurrent or metastatic cervical cancer.
      • Disease is persistent small cell neuroendocrine carcinoma of the cervix.

    Colorectal Cancer

    Covered when ALL of the following are met:

    ALL of the following

    • Disease is colorectal cancer, including anal adenocarcinoma.
    • The tumor is MSI-H, dMMR, or has a POLE/POLD1 mutation with an ultra-hypermutated phenotype, such as TMB greater than 50 mut/Mb.
    • Treatment is in combination with nivolumab for 4 doses followed by nivolumab as a single agent.

    Cutaneous Melanoma

    Covered in any of the following treatment settings:

    ANY of the following

    • Single agent for up to 4 doses, or in combination with nivolumab for 4 doses followed by nivolumab as a single agent, for metastatic or unresectable disease.
    • In combination with nivolumab for up to 4 doses followed by nivolumab as a single agent as adjuvant treatment of oligometastatic disease when there is no evidence of disease following systemic or metastasis-directed therapy, such as complete resection.
    • Single agent for up to 8 doses as adjuvant treatment of local satellite or in-transit recurrence, resectable disease, or oligometastatic disease after prior anti-PD-1 therapy.
    • Low dose in combination with pembrolizumab for up to 4 doses followed by pembrolizumab as a single agent for disease progression following anti-PD-1 therapy as subsequent therapy for metastatic or unresectable disease.

    Esophageal and Esophagogastric Junction Cancers

    Covered when the applicable disease and treatment conditions are met:

    ANY of the following

    • PD-L1-positive first-line or subsequent therapy

      • Member is not a surgical candidate or has unresectable locally advanced, recurrent, or metastatic esophageal or esophagogastric junction cancer.
      • Treatment is in combination with nivolumab.
      • ANY of the following

        • First-line therapy and PD-L1 is at least 1%.
        • Subsequent therapy.
    • Biomarker-defined disease

    Gastric Cancer

    Covered when ALL of the following are met:

    ALL of the following

    • Disease is gastric adenocarcinoma.
    • Tumor is MSI-H or dMMR.
    • Treatment is in combination with nivolumab.

    Gestational Trophoblastic Neoplasia

    Covered when ALL of the following are met:

    ALL of the following

    • Disease is multiagent chemotherapy-resistant gestational trophoblastic neoplasia.
    • ANY of the following

      • Member has recurrent or progressive intermediate trophoblastic tumor, including placental site trophoblastic tumor or epithelioid trophoblastic tumor.
      • Member has high-risk disease.
    • Treatment is in combination with nivolumab.

    Hepatocellular Carcinoma

    Covered when either treatment setting is met:

    ANY of the following

    • First-line treatment of unresectable or extrahepatic/metastatic hepatocellular carcinoma in combination with nivolumab for 4 doses followed by nivolumab as a single agent.
    • Subsequent treatment of hepatocellular carcinoma in combination with nivolumab for 4 doses followed by nivolumab as a single agent.

    Kaposi Sarcoma

    Covered when ALL of the following are met:

    ALL of the following

    • Disease is advanced Kaposi sarcoma that is relapsed or refractory.
    • Treatment is subsequent therapy in combination with nivolumab.

    Merkel Cell Carcinoma

    Covered when the disease meets the specified stage or setting criteria:

    ALL of the following

    • Disease is regional, in-transit, unresectable, recurrent, or stage IV Merkel cell carcinoma.
    • Treatment is a single agent or in combination with nivolumab.

    Non-Small Cell Lung Cancer

    Covered when ALL of the following are met:

    ALL of the following

    • Disease is recurrent, advanced, or metastatic NSCLC.
    • There are no EGFR exon 19 deletions or exon 21 L858R mutations, and no ALK, RET, or ROS1 gene fusions, unless testing is not feasible because of insufficient tissue.
    • The requested medication is used in a regimen containing nivolumab.

    Ovarian, Fallopian Tube, Primary Peritoneal Cancer

    Covered when ALL of the following are met:

    ALL of the following

    • Disease is progressive, persistent, or recurrent epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, clear cell carcinoma of the ovary, or hypercalcemic type small cell carcinoma of the ovary.
    • Treatment is in combination with nivolumab.

    Pleural or Peritoneal Mesothelioma

    Covered when ALL of the following are met:

    ALL of the following

    • Disease is pleural or peritoneal mesothelioma, including pericardial mesothelioma or tunica vaginalis testis mesothelioma.
    • Treatment is in combination with nivolumab.

    Initial Therapy: Additional Covered Malignancies

    The following additional malignancies are covered when the stated disease, biomarker, treatment setting, and regimen requirements are met. Authorization is generally for 6 months.

    ANY of the following

    • Renal cell carcinoma: relapsed, advanced, or stage IV disease with clear cell histology; use in combination with nivolumab for 4 doses followed by single-agent nivolumab.
    • Small bowel adenocarcinoma: unresectable, medically inoperable, advanced, or metastatic disease, or neoadjuvant treatment; tumor is MSI-H, dMMR, or POLE/POLD1 with an ultra-hypermutated phenotype such as TMB greater than 50 mut/Mb; use in combination with nivolumab for 4 doses followed by nivolumab as a single agent.
    • Soft tissue sarcoma: pleomorphic rhabdomyosarcoma, borderline or malignant phyllodes tumor of the breast, or epithelioid hemangioendothelioma with TMB-H of at least 10 mut/Mb, treated in combination with nivolumab; or angiosarcoma, dedifferentiated liposarcoma, extremity or body wall sarcoma, head or neck sarcoma, or retroperitoneal or intra-abdominal sarcoma treated in combination with nivolumab.
    • Uterine neoplasms: subsequent treatment of recurrent unresectable or metastatic endometrial carcinoma, or subsequent treatment of unresectable or metastatic uterine sarcoma, when TMB-H is at least 10 mut/Mb and there are no satisfactory alternative treatment options; use in combination with nivolumab.

    Cutaneous Melanoma Continuation Limits

    For continued treatment of cutaneous melanoma, authorization may be granted when there is no evidence of unacceptable toxicity or disease progression while on the current regimen and the applicable maximum dose limit has not been reached.

    ANY of the following

    • Single-agent adjuvant treatment of local satellite or in-transit recurrence, resectable disease, or oligometastatic disease.Up to 8 doses maximum
    • Combination with nivolumab for adjuvant treatment; neoadjuvant treatment; or single-agent, pembrolizumab, or nivolumab treatment for metastatic or unresectable disease.Up to 4 doses maximum
    • Neoadjuvant treatment.Up to 2 doses maximum

    Tennessee State Mandate Requirements

    BlueCross BlueShield of Tennessee's Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of FDA-approved drugs.

    ALL of the following

    • The off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

    Biomarker and Molecular Thresholds

    PD-L1 expression
    Threshold≥1%
    BiomarkerPD-L1 expression
    Applicable useCertain metastatic or recurrent non-small cell lung cancer and esophageal cancer indications
    Bone cancer tumor mutational burden
    Threshold≥10 mut/Mb
    BiomarkerTumor mutational burden-high (TMB-H)
    Applicable useUnresectable or metastatic bone cancer after progression following prior treatment when no satisfactory alternative options exist

    Authorization and Documentation Requirements

    Prior Authorization

    Obtain prior authorization before treatment

    Prior authorization is required for coverage review. The prescribed use must be a listed FDA-approved or compendial indication, all applicable approval criteria must be met, and required biomarker or molecular testing documentation must be submitted where applicable.

    Prior Authorization

    Request six-month authorization

    Prior authorization is required for ipilimumab coverage. Authorization may be granted for 6 months when the member’s diagnosis and requested regimen satisfy one of the disease-specific criteria in the policy.

    • Submit the diagnosis and requested regimen for review.
    • A 6-month authorization applies when the applicable disease-specific criteria are met.
    Prior Authorization

    Therapy Overview

    Ipilimumab (Yervoy) is used as an oncology therapy either as a single agent or in combination with nivolumab. Some covered indications also require combination treatment with platinum-doublet chemotherapy.

    Biomarker Definitions

    MSI-H/dMMR
    DefinitionTumor characterized by high microsatellite instability or deficient mismatch repair
    Related statusesMSI-H or dMMR
    DocumentationSubmit laboratory documentation confirming MSI-H, dMMR, or POLE/POLD1 tumor status where applicable
    MSI-H
    MeaningMicrosatellite instability-high tumor status
    Use in policyRequired for specified ampullary, appendiceal, colorectal, esophageal, and gastric cancer indications
    Evidence

    Initial Authorization Criteria

    Adrenocortical Carcinoma — Six-Month Initial Authorization

    Authorization of 6 months may be granted.

    Adrenocortical carcinoma: Use ipilimumab in combination with nivolumab for unresectable or metastatic adrenocortical carcinoma.

    Ampullary Adenocarcinoma — Six-Month Initial Authorization

    Authorization of 6 months may be granted.

    Ampullary adenocarcinoma: Use ipilimumab in combination with nivolumab for 4 doses followed by nivolumab as a single agent for progressive or metastatic MSI-H or dMMR ampullary adenocarcinoma.

    Adrenal, Ampullary, Appendiceal, Biliary, and Bone Cancers — Grouped Initial Criteria

    Initial authorization may be granted for 6 months when one disease-specific criterion is met.

    Continuation and Reauthorization Criteria

    General Continuation Therapy — Six-Month Reauthorization

    Authorization of 6 months may be granted for continued treatment when the member remains clinically eligible.

    General continuation requirements: The requested indication is listed in the coverage criteria; there is no unacceptable toxicity or disease progression while on the current regimen; and any applicable maximum dose or total treatment duration has not been exceeded.

    For indications without a specified limited number of doses, continuation may be authorized when treatment guidelines do not specify a limited total dose.

    Continuation With Up to 4-Dose Maximum

    Authorization may be granted for 6 months when the member remains eligible.

    Limited-dose continuation: The member requests reauthorization for ampullary adenocarcinoma, appendiceal neoplasms or cancers, colorectal cancer, hepatocellular cancer, renal cell carcinoma, small bowel adenocarcinoma, or uveal melanoma; there is no unacceptable toxicity or disease progression; and 4 doses have not already been received.Up to 4 doses maximum

    Medication Dosing and Authorization Limits

    Ipilimumab
    Authorization period6 months
    MedicationIpilimumab (Yervoy)
    BasisDiagnosis and requested regimen must satisfy a disease-specific coverage criterion
    Yervoy (ipilimumab)
    MedicationYervoy (ipilimumab)
    Regimen1 mg/kg every 6 weeks
    RouteIntravenous

    Administration Requirements

    Billing Rule

    Administer listed regimens intravenously

    Use an infusion center for the listed maximum dosing regimens because the policy specifies intravenous administration.

    • Bill and administer the regimen according to the diagnosis-specific maximum dosing limits.
    • Confirm the route of administration is intravenous.
    Policy Summary
    PayerBlueCross BlueShield of Tennessee
    PolicyIpilimumab (Yervoy) Coverage Criteria
    Policy CodePolicy ID_CHS_17962026a_1026
    Change TypeNo material clinical or coverage changes
    Effective DateDec 31, 202642d
    Next Review DateN/A
    Key ActionSubmit laboratory documentation confirming MSI-H, dMMR, or POLE/POLD1 tumor status when applicable.
    SourceLink
    On This Page
    Covered Indications and EligibilityBiomarker and Molecular ThresholdsAuthorization and Documentation RequirementsTherapy OverviewBiomarker DefinitionsInitial Authorization CriteriaContinuation and Reauthorization CriteriaMedication Dosing and Authorization LimitsAdministration Requirements
    The tumor is TMB-H.
  1. Treatment is in combination with nivolumab.
  2. In combination with nivolumab for up to 2 doses followed by nivolumab as a single agent as neoadjuvant treatment.
    • Esophageal or esophagogastric junction cancer is MSI-H or dMMR.
    • Treatment is in combination with nivolumab.
  3. Induction therapy

    • Member has esophageal or esophagogastric junction squamous cell carcinoma with PD-L1 at least 1%.
    • Treatment is intended to relieve dysphagia and is planned before esophagectomy.
    • Treatment is in combination with nivolumab.
  4. Uveal melanoma: unresectable or metastatic disease treated as a single agent or in combination with nivolumab for 4 doses followed by nivolumab as a single agent.
  5. Vaginal cancer: recurrent or metastatic disease treated as subsequent therapy in combination with nivolumab.
  6. Vulvar cancer: advanced or recurrent/metastatic disease treated as subsequent therapy in combination with nivolumab.
  7. Ultra-hypermutated tumor burden example
    Example threshold>50 mut/Mb
    PhenotypeUltra-hypermutated tumor phenotype
    Applicable diseasesAppendiceal neoplasms and cancers, and colorectal cancer including anal adenocarcinoma
    Esophageal and esophagogastric junction cancer PD-L1
    Threshold≥1
    BiomarkerPD-L1 expression
    Applicable useFirst-line or induction treatment settings for specified esophageal or esophagogastric junction cancers
    Ultra-hypermutated tumor
    Example definitionTumor mutational burden greater than 50 mutations per megabase
    Associated statusMSI-H, dMMR, or POLE/POLD1 tumor status
    DocumentationLaboratory documentation confirming applicable tumor biomarker status is required
    Tumor mutational burden-high
    Threshold≥10 mut/Mb
    StatusTumor mutational burden-high (TMB-H or TMBH)
    Applicable usesSpecified soft tissue sarcoma and uterine neoplasm indications

    Match the request to an indication-specific criterion

    Prior authorization may be granted for 6 months when ipilimumab meets an indication-specific coverage criterion. Confirm the required disease status, treatment setting, biomarker status, and combination regimen before submitting the request.

    • Some indications require use with nivolumab.
    • Some indications require four ipilimumab doses followed by nivolumab as a single agent.
    • Use the indication-specific criteria for the applicable malignancy.
    Documentation Required

    Document required tumor biomarkers

    Submit laboratory documentation confirming microsatellite instability-high (MSI-H), mismatch repair deficient (dMMR), or polymerase epsilon/delta (POLE/POLD1) tumor status, where applicable.

    • Include the applicable laboratory report with the prior authorization submission.
    Documentation Required

    Provide molecular testing results

    Submit documentation confirming the absence of EGFR exon 19 deletion and exon 21 L858R mutations, ALK fusions, RET fusions, and ROS1 fusions when applicable.

    • Document the applicable molecular test results.
    • For NSCLC, the absence of these alterations is required unless testing is not feasible because of insufficient tissue.
    Documentation Required

    Submit complete clinical eligibility documentation

    Documentation should establish the cancer diagnosis, disease status, treatment setting, relevant histology, required biomarker results, and the requested combination regimen or lack of satisfactory alternatives when required.

    • Document MSI-H, dMMR, POLE/POLD1 ultra-hypermutated phenotype, or TMB-high status when required.
    • Document the applicable disease status, such as recurrent, metastatic, unresectable, or progressive disease.
    • Document required use with nivolumab or another specified regimen.
    • For uterine neoplasms, document the lack of satisfactory alternative treatment options when required.
    Documentation Required

    Document eligibility for continuation

    For reauthorization, document ongoing treatment, absence of unacceptable toxicity or disease progression, prior doses received when a dose maximum applies, and total treatment duration when a duration limit applies.

    • Confirm that the requested indication remains covered.
    • Report the number of doses already received when a dose maximum applies.
    • Report total treatment duration when a duration limit applies.
    Denial Risk

    Avoid unlisted indications

    Use for indications other than the listed FDA-approved or compendial uses is considered experimental/investigational and not medically necessary. An unlisted indication may therefore result in denial of coverage.

    • Verify that the requested use is listed before initiating treatment or submitting the request.
    Denial Risk

    Check toxicity, progression, and treatment limits

    Reauthorization may be denied when there is unacceptable toxicity or disease progression on the current regimen, or when the applicable maximum number of doses or total treatment duration has been reached.

    • Several indications are limited to up to 4 doses.
    • Specified cutaneous melanoma pathways may be limited to 8, 4, or 2 doses.
    • Some indications have total-treatment limits, including up to 24 months or 2 to 6 months for biliary tract cancer in the neoadjuvant setting.
    Denial Risk

    Verify uterine neoplasm eligibility

    For recurrent unresectable or metastatic endometrial carcinoma or unresectable/metastatic uterine sarcoma, coverage requires tumor mutational burden-high disease of at least 10 mutations per megabase and no satisfactory alternative treatment options.

    • Request subsequent treatment in combination with nivolumab.
    • Document TMB-high status: ≥10 mut/Mb.
    • Document that no satisfactory alternative treatment options are available.
    Laboratory report confirming tumor status
    dMMR
    MeaningMismatch repair deficient tumor status
    Use in policyRequired for specified ampullary, appendiceal, colorectal, esophageal, and gastric cancer indications
    EvidenceLaboratory report confirming tumor status
    POLE/POLD1 ultra-hypermutated phenotype
    AlterationsPolymerase epsilon or polymerase delta (POLE/POLD1) tumor alterations
    PhenotypeUltra-hypermutated tumor phenotype
    Example burdenTumor mutational burden greater than 50 mutations per megabase
    TMB-H
    MeaningTumor mutational burden-high status
    Bone cancer thresholdAt least 10 mutations per megabase
    Other policy usesSpecified biliary tract cancer and other oncology indications use TMB-H criteria
    PD-L1 ≥1
    MeaningProgrammed death-ligand 1 expression level of at least 1
    Lung cancer expression thresholdPD-L1 ≥1%
    Esophageal cancer expression thresholdPD-L1 ≥1
    Ultra-hypermutated phenotype
    Included statusesMSI-H, dMMR, or POLE/POLD1 tumor status
    PhenotypeUltra-hypermutated tumor phenotype
    ExampleTumor mutational burden greater than 50 mutations per megabase
    TMB-high (TMBH)
    DefinitionTumor mutational burden-high (TMBH)
    ThresholdAt least 10 mutations per megabase
    Applicable policy examplesSpecified soft tissue sarcoma and uterine neoplasm coverage

    Disease-specific initial criteria

    • Unresectable or metastatic adrenocortical carcinoma treated with nivolumab combination therapy.
    • Progressive or metastatic MSI-H or dMMR ampullary adenocarcinoma treated with nivolumab for 4 doses followed by nivolumab alone.
    • Qualifying appendiceal neoplasm or cancer with MSI-H, dMMR, or POLE/POLD1 ultra-hypermutated phenotype treated with nivolumab for 4 doses followed by nivolumab alone.
    • TMB-H cholangiocarcinoma or gallbladder cancer in a specified subsequent or neoadjuvant setting treated with nivolumab.
    • Unresectable or metastatic TMB-H bone cancer that progressed after prior treatment, has no satisfactory alternative, and is treated with nivolumab.

    Melanoma, Cervical, Colorectal, Esophageal, and Esophagogastric Junction Cancers — Grouped Initial Criteria

    Initial authorization may be granted for 6 months when one disease-specific criterion is met.

    Disease-specific initial criteria

    • CNS brain metastases in BRAF non-specific melanoma treated with single-agent ipilimumab or nivolumab combination therapy for 4 doses followed by nivolumab alone.
    • Recurrent or metastatic cervical cancer, or persistent small cell neuroendocrine carcinoma of the cervix, treated with nivolumab.
    • MSI-H, dMMR, or POLE/POLD1 ultra-hypermutated colorectal cancer, including anal adenocarcinoma, treated with nivolumab for 4 doses followed by nivolumab alone.
    • Cutaneous melanoma meeting a covered metastatic, unresectable, adjuvant, recurrent, resectable, oligometastatic, or neoadjuvant treatment pathway.
    • Esophageal or esophagogastric junction cancer meeting the specified first-line, subsequent, biomarker-defined, or dysphagia-induction criteria and treated with nivolumab.

    Additional Oncology Indications — Grouped Six-Month Initial Criteria

    Initial authorization may be granted for 6 months when one disease-specific criterion is met.

    Additional oncology indications

    • MSI-H or dMMR gastric adenocarcinoma treated with nivolumab.
    • Multiagent chemotherapy-resistant gestational trophoblastic neoplasia meeting the specified recurrent, progressive, intermediate, or high-risk disease criteria and treated with nivolumab.
    • Unresectable or extrahepatic/metastatic hepatocellular carcinoma in first-line or subsequent treatment, with nivolumab for 4 doses followed by nivolumab alone.
    • Relapsed or refractory advanced Kaposi sarcoma treated subsequently with nivolumab.
    • Regional, in-transit, unresectable, recurrent, or stage IV Merkel cell carcinoma treated with single-agent ipilimumab or nivolumab combination therapy.
    • Recurrent, advanced, or metastatic NSCLC meeting the molecular testing requirements and treated in a nivolumab-containing regimen.
    • Progressive, persistent, or recurrent ovarian, fallopian tube, or primary peritoneal cancer, including specified ovarian histologies, treated with nivolumab.
    • Pleural or peritoneal mesothelioma, including specified pericardial or tunica vaginalis testis mesothelioma, treated with nivolumab.

    Initial Therapy — Indication-Specific Criteria and Six-Month Authorization

    Authorization of 6 months may be granted when the indication-specific criteria are met.

    Indication-specific initial therapy: The member has a covered malignancy and the requested ipilimumab regimen, disease status, biomarker status, and treatment setting meet the applicable policy requirement.

    Several indications require nivolumab combination therapy; some require 4 ipilimumab doses followed by nivolumab monotherapy.

    Disease-Specific Continuation Limits

    Authorization may be granted for continued treatment when the member remains clinically eligible.

    Disease-specific continuation: The member requests reauthorization for biliary tract cancer, bone cancer, cervical cancer, esophageal or esophagogastric junction cancer, Kaposi sarcoma, NSCLC, pleural or peritoneal mesothelioma, soft tissue sarcoma, uterine neoplasms, vaginal cancer, or vulvar cancer, with no unacceptable toxicity or disease progression on the current regimen.Biliary tract cancer: 2–6 months total for neoadjuvant treatment or up to 24 months total in other settings; all other listed indications: up to 24 months total

    Cutaneous Melanoma Continuation — Criteria and Maximum Dose Limit

    Authorization may be granted for continued cutaneous melanoma treatment.

    Cutaneous melanoma continuation: The applicable treatment pathway is met, the member has no unacceptable toxicity or disease progression, and the applicable maximum number of doses has not been received.Up to 8 doses for specified single-agent adjuvant therapy; up to 4 doses for combination adjuvant, neoadjuvant, or metastatic/unresectable therapy; up to 2 doses for the specified neoadjuvant pathway
    Yervoy (ipilimumab)
    MedicationYervoy (ipilimumab)
    Regimen1 mg/kg every 6 weeks
    AdministrationIntravenous, per course
    Yervoy (ipilimumab)
    Induction1 mg/kg every 3 weeks for 4 doses
    Maintenance1 mg/kg every 6 weeks
    RouteIntravenous
    Yervoy (ipilimumab)
    MedicationYervoy (ipilimumab)
    Regimen1 mg/kg every 6 weeks
    RouteIntravenous
    Yervoy (ipilimumab)
    Induction3 mg/kg every 3 weeks for 4 doses
    Maintenance1 mg/kg every 6 weeks
    RouteIntravenous
    Yervoy (ipilimumab)
    Option 11 mg/kg every 6 weeks
    Option 23 mg/kg every 3 weeks for 4 doses
    Option 310 mg/kg every 3 weeks for 4 doses followed by 10 mg/kg every 12 weeks beginning with week 24
    Yervoy (ipilimumab)
    Induction regimen1 mg/kg every 3 weeks for 4 doses
    MedicationYervoy (ipilimumab)
    RouteIntravenous
    Yervoy (ipilimumab)
    MedicationYervoy (ipilimumab)
    Regimen1 mg/kg every 6 weeks
    RouteIntravenous
    Yervoy (ipilimumab)
    Regimen1 mg/kg every 6 weeks for 2–3 doses
    MedicationYervoy (ipilimumab)
    RouteIntravenous
    Yervoy (ipilimumab)
    MedicationYervoy (ipilimumab)
    Regimen1 mg/kg every 6 weeks
    RouteIntravenous
    Yervoy (ipilimumab)
    Induction regimen3 mg/kg every 3 weeks for 4 doses
    MedicationYervoy (ipilimumab)
    RouteIntravenous
    Yervoy (ipilimumab)
    MedicationYervoy (ipilimumab)
    Regimen1 mg/kg every 6 weeks
    RouteIntravenous
    Yervoy (ipilimumab)
    Induction regimen3 mg/kg every 3 weeks for 4 doses
    MedicationYervoy (ipilimumab)
    RouteIntravenous
    Yervoy (ipilimumab)
    Induction3 mg/kg every 3 weeks for 4 doses
    Maintenance3 mg/kg every 12 weeks
    MaximumUp to 4 maintenance doses
    Yervoy (ipilimumab)
    Induction regimen3 mg/kg every 3 weeks for 4 doses
    MedicationYervoy (ipilimumab)
    RouteIntravenous
    Yervoy (ipilimumab)
    MedicationYervoy (ipilimumab)
    Regimen1 mg/kg every 6 weeks
    RouteIntravenous
    Yervoy (Ipilimumab)
    Regimen1 mg/kg every 6 weeks for 2–3 doses
    Diagnosis contextGastric cancer
    RouteIntravenous
    Yervoy (Ipilimumab)
    MedicationYervoy (ipilimumab)
    Regimen1 mg/kg every 6 weeks
    Diagnosis contextGestational trophoblastic neoplasia
    Yervoy (Ipilimumab)
    Induction regimen3 mg/kg every 3 weeks for 4 doses
    Diagnosis contextHepatocellular carcinoma
    RouteIntravenous
    Yervoy (Ipilimumab)
    MedicationYervoy (ipilimumab)
    Regimen1 mg/kg every 6 weeks
    Diagnosis contextKaposi sarcoma
    Yervoy (Ipilimumab)
    Induction3 mg/kg every 3 weeks for 4 doses
    Maintenance3 mg/kg every 12 weeks
    MaximumUp to 4 maintenance doses
    Yervoy (Ipilimumab)
    Induction regimen3 mg/kg every 3 weeks for 4 doses
    Diagnosis contextMerkel cell carcinoma
    RouteIntravenous
    Yervoy (Ipilimumab)
    MedicationYervoy (ipilimumab)
    Regimen1 mg/kg every 6 weeks
    Diagnosis contextPleural, peritoneal, or pericardial mesothelioma
    Yervoy (Ipilimumab)
    Regimen1 mg/kg every 6 weeks for 2–3 doses
    MedicationYervoy (ipilimumab)
    RouteIntravenous
    Yervoy
    MedicationYervoy
    Regimen1 mg/kg every 6 weeks
    Diagnosis contextNon-small cell lung cancer
    Yervoy (Ipilimumab)
    Induction1 mg/kg every 3 weeks for 4 doses
    Maintenance1 mg/kg every 6 weeks
    Diagnosis contextOvarian, fallopian tube, or primary peritoneal cancer
    Yervoy (Ipilimumab)
    Maintenance1 mg/kg every 6 weeks
    Induction option1 mg/kg every 3 weeks for 4 doses
    Diagnosis contextRenal cell carcinoma
    Yervoy (Ipilimumab)
    Induction regimen1 mg/kg every 3 weeks for 4 doses
    MedicationYervoy (ipilimumab)
    RouteIntravenous
    Yervoy(Ipilimumab)
    Induction1 mg/kg every 3 weeks for 4 doses
    Maintenance1 mg/kg every 6 weeks
    Diagnosis contextSoft tissue sarcoma
    Yervoy (Ipilimumab)
    MedicationYervoy (ipilimumab)
    Regimen1 mg/kg every 6 weeks
    Diagnosis contextUterine neoplasms including endometrial carcinoma
    Yervoy (Ipilimumab)
    Induction3 mg/kg every 3 weeks for 4 doses
    Maintenance1 mg/kg every 6 weeks
    Diagnosis contextVaginal cancer
    Yervoy (Ipilimumab)
    Induction3 mg/kg every 3 weeks for 4 doses
    Maintenance1 mg/kg every 6 weeks
    Diagnosis contextVulvar cancer